Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > Articles online first > The Journal of Cardiovascular Surgery 2021 Apr 08

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

The Journal of Cardiovascular Surgery 2021 Apr 08

DOI: 10.23736/S0021-9509.21.11769-0

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Outcomes of biosynthetic vascular graft for infrainguinal femoro-popliteal and femorodistal revascularization

Anna Maria SOCRATE 1 , Benedetta SPAMPINATO 2, Gianmarco ZUCCON 2, Matteo FERRARIS 1, Adolfo COSTANTINI 1, Gabriele PIFFARETTI 3

1 Vascular Surgery, ASST Ovest Milanese, Legnano, Italy; 2 Postgraduate School in Vascular Surgery, University of Milan, Milan, Italy; 3 Vascular Surgery, Department of Medicine and Surgery, University of Insubria School of Medicine, Varese, Italy


PDF


BACKGROUND: To retrospectively analyze early and late outcomes of infrainguinal revascularization performed with the Omniflow-II® biosynthetic vascular graft (BVG) for complex femoro-popliteal obstructive disease.
METHODS: Over a 10-year period, this BVG was used in 110 patients who underwent infrainguinal femoro-popliteal or femoro-distal bypass. Early (intraoperative and <30 days) results were analyzed in terms of death, thrombosis, amputations and reinterventions. Follow-up results were analyzed in terms of primary and secondary graft patency, and amputation-free survival.
RESULTS: We performed 87 (79.1%) above-the-knee bypass, 20 (18.2%) below-the-knee bypass, and 3 (2.7%) tibial artery bypass. In-hospital mortality was not observed. Mean follow-up was 66 ± 37 months (range, 3-150). Estimated primary patency rate at 1, 2 and 5-years of follow-up was 77% ± 4 (95%CI: 68-84), 73% ± 5 (95%CI: 63.5-83), and 59% ± 6 (95%CI: 47-70.5) respectively. Predictors of primary patency loss were the presence of critical limb ischemia (P = 0.048; HR: 2.1; 95%CI: 1.01-4.28), and the necessity of belowthe-knee bypass (P = 0.012; HR: 2.4; 95%CI: 1.22-4.75). Aneurysmal degeneration of the BVG was detected in 4 (3.6%) patients, an infected BVG occurred in 3 (2.7%) patients. The amputation-free survival was 96% ± 2 (95%CI: 91-99), 93% ± 3 (95%CI: 86-96), and 76% ± 5 (95%CI: 66-84) at 1, 2 and 5-years respectively.
CONCLUSIONS: In our experience, Omniflow-II® is a valid first-line alternative for infrainguinal revascularization when the ipsilateral autologous saphenous vein is not available. Aneurysmal degeneration was lower than previously reported with alternative BVGs, and the incidence of BVG infection was acceptably low.


KEY WORDS: Biosynthetic vascular graft; Omniflow II; Femoro-popliteal bypass

top of page